vs
EXACT SCIENCES CORP（EXAS）与Rivian Automotive, Inc.（RIVN）财务数据对比。点击上方公司名可切换其他公司
Rivian Automotive, Inc.的季度营收约是EXACT SCIENCES CORP的1.5倍（$1.3B vs $878.4M），EXACT SCIENCES CORP净利率更高（-9.8% vs -63.1%，领先53.3%），EXACT SCIENCES CORP同比增速更快（23.1% vs -25.8%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-1.1B），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 3.3%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Rivian Automotive是2009年成立的美国电动汽车制造商及汽车科技企业，主打基于自研滑板平台打造的电动SUV、皮卡及EDV电动配送货车，旗下R1T皮卡于2021年末正式开启交付，还计划于2023年底前在美国和加拿大布局专属充电网络，其平台可适配新车型也可对外授权使用。
EXAS vs RIVN — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.3B |
| 净利润 | $-86.0M | $-811.0M |
| 毛利率 | 70.1% | 9.3% |
| 营业利润率 | -9.4% | -64.8% |
| 净利率 | -9.8% | -63.1% |
| 营收同比 | 23.1% | -25.8% |
| 净利润同比 | 90.1% | -9.0% |
| 每股收益（稀释后） | $-0.45 | $-0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $878.4M | $1.3B | ||
| Q3 25 | $850.7M | $1.6B | ||
| Q2 25 | $811.1M | $1.3B | ||
| Q1 25 | $706.8M | $1.2B | ||
| Q4 24 | $713.4M | $1.7B | ||
| Q3 24 | $708.7M | $874.0M | ||
| Q2 24 | $699.3M | $1.2B | ||
| Q1 24 | $637.5M | $1.2B |
| Q4 25 | $-86.0M | $-811.0M | ||
| Q3 25 | $-19.6M | $-1.2B | ||
| Q2 25 | $-1.2M | $-1.1B | ||
| Q1 25 | $-101.2M | $-545.0M | ||
| Q4 24 | $-864.6M | $-744.0M | ||
| Q3 24 | $-38.2M | $-1.1B | ||
| Q2 24 | $-15.8M | $-1.5B | ||
| Q1 24 | $-110.2M | $-1.4B |
| Q4 25 | 70.1% | 9.3% | ||
| Q3 25 | 68.6% | 1.5% | ||
| Q2 25 | 69.3% | -15.8% | ||
| Q1 25 | 70.8% | 16.6% | ||
| Q4 24 | 69.0% | 9.8% | ||
| Q3 24 | 69.4% | -44.9% | ||
| Q2 24 | 69.8% | -38.9% | ||
| Q1 24 | 70.0% | -43.8% |
| Q4 25 | -9.4% | -64.8% | ||
| Q3 25 | -3.0% | -63.1% | ||
| Q2 25 | -0.3% | -85.5% | ||
| Q1 25 | -13.6% | -52.8% | ||
| Q4 24 | -122.8% | -38.1% | ||
| Q3 24 | -5.6% | -133.8% | ||
| Q2 24 | -3.8% | -118.7% | ||
| Q1 24 | -16.7% | -123.3% |
| Q4 25 | -9.8% | -63.1% | ||
| Q3 25 | -2.3% | -75.3% | ||
| Q2 25 | -0.1% | -85.7% | ||
| Q1 25 | -14.3% | -44.0% | ||
| Q4 24 | -121.2% | -42.9% | ||
| Q3 24 | -5.4% | -125.9% | ||
| Q2 24 | -2.3% | -125.8% | ||
| Q1 24 | -17.3% | -120.1% |
| Q4 25 | $-0.45 | $-0.66 | ||
| Q3 25 | $-0.10 | $-0.96 | ||
| Q2 25 | $-0.01 | $-0.97 | ||
| Q1 25 | $-0.54 | $-0.48 | ||
| Q4 24 | $-4.69 | $-0.67 | ||
| Q3 24 | $-0.21 | $-1.08 | ||
| Q2 24 | $-0.09 | $-1.46 | ||
| Q1 24 | $-0.60 | $-1.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $6.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $4.6B |
| 总资产 | $5.9B | $14.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $964.7M | $6.1B | ||
| Q3 25 | $1.0B | $7.1B | ||
| Q2 25 | $858.4M | $7.5B | ||
| Q1 25 | $786.2M | $7.2B | ||
| Q4 24 | $1.0B | $7.7B | ||
| Q3 24 | $1.0B | $6.7B | ||
| Q2 24 | $946.8M | $7.9B | ||
| Q1 24 | $652.1M | $7.9B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $5.5B | ||
| Q1 24 | — | $4.4B |
| Q4 25 | $2.4B | $4.6B | ||
| Q3 25 | $2.5B | $5.1B | ||
| Q2 25 | $2.5B | $6.1B | ||
| Q1 25 | $2.4B | $6.2B | ||
| Q4 24 | $2.4B | $6.6B | ||
| Q3 24 | $3.2B | $5.9B | ||
| Q2 24 | $3.2B | $6.8B | ||
| Q1 24 | $3.1B | $8.1B |
| Q4 25 | $5.9B | $14.9B | ||
| Q3 25 | $5.9B | $15.2B | ||
| Q2 25 | $5.8B | $15.6B | ||
| Q1 25 | $5.7B | $15.5B | ||
| Q4 24 | $5.9B | $15.4B | ||
| Q3 24 | $6.7B | $14.3B | ||
| Q2 24 | $6.7B | $15.4B | ||
| Q1 24 | $6.4B | $15.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.81× | ||
| Q1 24 | — | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $-681.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $-1.1B |
| 自由现金流率自由现金流/营收 | 13.7% | -89.0% |
| 资本支出强度资本支出/营收 | 3.6% | 36.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $-2.5B |
8季度趋势，按日历期对齐
| Q4 25 | $151.7M | $-681.0M | ||
| Q3 25 | $219.9M | $26.0M | ||
| Q2 25 | $89.0M | $64.0M | ||
| Q1 25 | $30.8M | $-188.0M | ||
| Q4 24 | $47.1M | $1.2B | ||
| Q3 24 | $138.7M | $-876.0M | ||
| Q2 24 | $107.1M | $-754.0M | ||
| Q1 24 | $-82.3M | $-1.3B |
| Q4 25 | $120.4M | $-1.1B | ||
| Q3 25 | $190.0M | $-421.0M | ||
| Q2 25 | $46.7M | $-398.0M | ||
| Q1 25 | $-365.0K | $-526.0M | ||
| Q4 24 | $10.7M | $856.0M | ||
| Q3 24 | $112.6M | $-1.2B | ||
| Q2 24 | $71.2M | $-1.0B | ||
| Q1 24 | $-120.0M | $-1.5B |
| Q4 25 | 13.7% | -89.0% | ||
| Q3 25 | 22.3% | -27.0% | ||
| Q2 25 | 5.8% | -30.5% | ||
| Q1 25 | -0.1% | -42.4% | ||
| Q4 24 | 1.5% | 49.4% | ||
| Q3 24 | 15.9% | -131.9% | ||
| Q2 24 | 10.2% | -89.6% | ||
| Q1 24 | -18.8% | -126.5% |
| Q4 25 | 3.6% | 36.0% | ||
| Q3 25 | 3.5% | 28.7% | ||
| Q2 25 | 5.2% | 35.5% | ||
| Q1 25 | 4.4% | 27.3% | ||
| Q4 24 | 5.1% | 18.9% | ||
| Q3 24 | 3.7% | 31.7% | ||
| Q2 24 | 5.1% | 24.4% | ||
| Q1 24 | 5.9% | 21.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RIVN
| Automotive Segment | $839.0M | 65% |
| Software And Services Segment | $447.0M | 35% |
| Regulatory Credits | $30.0M | 2% |
